GlassScriptPhysician profile
Jacqueline M Breen
NPI 1972786200
$1,362.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $256 · 2021: $756 · 2022: $350.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $266.17 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $257.55 | 2020-2022 | |
| Novo Nordisk INC | $248.65 | 2020-2021 | |
| Abbvie INC. | $168.50 | 2021-2022 | |
| Lilly USA, LLC | $165.01 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $57.71 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.22 | 2021-2022 | |
| Abbott Laboratories | $32.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.80 | 2022 | |
| Amarin Pharma, INC. | $17.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.86 | 2022 | |
| Medtronic USA, INC. | $15.39 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.46 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.